hotspot -WSS

hotspot

author：explore 2025-09-30 00:39:09 - browse：25937

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Drug for rare kidney disease narrowly misses mark in clinical trial

focus

WSS

STAT Summit: Ending the crisis of Black deaths in the U.S.

J&J lung cancer data amount to new salvo against AstraZeneca

The problems with dementia villages

UnitedHealth, Optum discontinue NaviHealth name

Thermo Fisher plant for manufacturing gene therapies to expand

How AI helped researchers track recovery from depression

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Senators: Long

Wildfire smoke exposes gaps in outdoor worker protections

STAT Readout Newsletter: Biotech news today

Cancer drug shortages should be causing more outrage

Questions loom on AstraZeneca cancer drug as safety concerns ebb

New air purifier tech could be key to improving indoor air quality

UnitedHealth, Optum discontinue NaviHealth name

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Results on Novartis prostate cancer therapy could expand its use

knowledge

The problems with dementia villages

Changes to biosimilar regulatory framework must prioritize patients

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Roche drug slashes death risk in early

Senate HELP committee spars over health care workforce policies

Experts study whether long Covid risk adds up with each reinfection

Wikipedia

hotspot

focus

hotspot